News

Telstar is a multinational group based in Spain that develops technology projects, equipment and services in the biotechnology, nanotechnology, traditional technology and medicine fields. With this agreement, Telstar

Watson claims that its Oxycodone Hydrochloride extended-release tablets are the generic version of Purdue Pharma’s treatment, OxyContin for the management of moderate to severe when continuous, around-the-clock opioid

Under the contract, TPP and the University of Aberdeen expect to work on the commercialization opportunities in the areas of nervous system disorders, immunology/inflammation and oncology. University of

Earlier, the company has received $5m grant from the NMSS in partnership with the NMSS’s Southern California chapter, with support from the National Institutes of Health, and $860,440

Teduglutide is a novel, recombinant analogue of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. Nycomed said the MAA for Teduglutide was

Almac claims FLT provides an antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. BioFocus has launched an

ADX71149 has been discovered under the collaboration between Addex and Ortho-McNeil-Janssen Pharmaceuticals. As per the terms of the agreement, Addex is entitled to receive up to EUR112m in

Lucentis, a vascular endothelial growth factor (VEGF) inhibitor, was first approved by the US Food and Drug Administration for the treatment of neovascular (wet) age-related macular degeneration (AMD)

As the primary objective of the trial, Versartis will assess the safety and tolerability of a single subcutaneous dose of VRS-317 in the trial. The company expects to